Source link : https://www.newshealth.biz/health-news/benralizumab-decreases-eosinophils-but-not-symptoms-in-eoe/
Benralizumab, an anti–interleukin-5 receptor alpha monoclonal antibody, was significantly better than placebo at producing a histologic response of up to six eosinophils per high-power field (eos/hpf) in patients with eosinophilic esophagitis (EoE), according to a new randomized study. At 24 weeks, 80.8% more patients in the benralizumab group had a histologic response than those in […]
Author : News Health
Publish date : 2024-07-29 13:31:53
Copyright for syndicated content belongs to the linked Source.